Tuesday, February 13, 2018 12:56:21 PM
As I said I am not totally informed but at least, here is what I think I know :
1- The company is fighting legal battles in multiple states as well as federal court.
2- The company is fighting legal battles in multiple states as well as federal court without reasonable certainty relative to the collectibility of these legal judgements.
3- The Company says it keeps exploring strategic alternatives. (They’ve said that for 6 years)
4- These alternatives include building upon Veltex's current settlements, property and other potentially marketable assets.
5- These alternatives could include selling, partnering, or raising capital to operate as a stand-alone firm.
What I potentially could work at (assumign what I do not know is not a critical onfo) would be to define and implement the following strategy.
I would immediately adopt the alternative generating some concrete value by selling to : ‘whomever wants to buy by either issuing cash or share of their own company.
The proceeds would then be distributed to current shareholders.
These shareholders could thereafter manage their individual shares of the proceeds, without waiting another 6 years to unfreeze the investment they currently have in VLXC (presumably already worth more than 15 cents or so per share).
The alternative I would reject from now on would be to operate a stand-alone company. This most likely, would require immediate dilution of our holdings (requirement for additional capital), present a relatively high risk short term (current market conditions and USA current political environment) and only present current shareholders with very long term potential gain… if any ???
We currently have paid partners who came on board to presumably realize such a strategy but unless current management stops running after multiple competing alternatives, the already (to ?) long wait runs the risk to keep going forever.
After all : 'A bird in the hand is worth two in the bush'
Patiently,
Roger
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM